Ascletis, the license partner for Sagimet’s denifanstat (ASC40) in China, released 52‑week topline data from its open‑label Phase 3 trial (ASC40‑304). The study enrolled 240 patients with moderate‑to‑severe acne vulgaris who received 50 mg of denifanstat once daily for up to 40 weeks, with a cumulative 52‑week exposure for those originally randomized to the drug in the preceding double‑blind Phase 3 trial.
Safety results were favorable, with no new or unexpected adverse events reported over the 52‑week period. The most common treatment‑emergent adverse events were dry eye (5.5 %) and dry skin (5.2 %), both mild to moderate and consistent with the drug’s known profile. No denifanstat‑related serious adverse events were observed, underscoring the long‑term tolerability of the FASN‑inhibitor approach.
Efficacy outcomes surpassed the 12‑week data from the earlier randomized trial. The open‑label extension showed greater reductions in Investigator Global Assessment scores, total skin lesion counts, and inflammatory lesion counts, indicating sustained clinical benefit over a full year. The 52‑week data confirm that denifanstat’s mechanism—direct inhibition of sebum production and inflammation—delivers durable improvement in a patient population that remains underserved by current therapies.
The results reinforce Sagimet’s broader strategy to commercialize denifanstat outside the United States and provide additional confidence in the platform’s therapeutic value. The 52‑week safety and efficacy profile strengthens the case for regulatory submissions in China and may accelerate revenue generation from the partnership with Ascletis. Management highlighted the significance of the data, noting that “the topline results from Ascletis’ Phase 3 open‑label acne trial build additional confidence in the clinical potential of FASN inhibition in acne.”
The market reaction was strongly positive, driven by the sustained safety and efficacy data over an extended period. Investors viewed the 52‑week results as a critical milestone that validates the FASN‑inhibition technology and supports the company’s pipeline, including the FDA Breakthrough Therapy designation for denifanstat in non‑cirrhotic MASH. The data also signal a clear regulatory path in China, where Ascletis’ New Drug Application for denifanstat has recently been accepted by the China National Medical Products Administration. Overall, the announcement positions Sagimet to capture a significant share of the acne market and to leverage its platform for other indications.
The denifanstat platform is part of a broader portfolio that includes TVB‑3567, a second oral FASN inhibitor in Phase 1 for acne, and ongoing development in metabolic disorders. The 52‑week data add weight to Sagimet’s claim that FASN inhibition offers a novel, antibiotic‑free approach to acne, potentially reducing reliance on topical retinoids and systemic antibiotics. The sustained benefit and favorable safety profile strengthen the company’s competitive positioning and support future revenue growth in both dermatology and metabolic disease markets.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.